Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Overcoming Therapy Resistance in Multiple Myeloma with Oncolytic Virotherapy and Immune Checkpoint Inhibition

FY 2017-18

Summary
Multiple Myeloma (MM), a blood cancer of antibody-producing plasma cells, has a five-year survival rate of less than 50%. As such, novel therapeutic strategies for this disease are needed. One of the factors contributing to poor survival outcomes in MM is its innate ability to avoid immune destruction. Therefore, therapeutic strategies would ideally enhance the host's immune response against these malignant cells. One such strategy would be the utilization of oncolytic viruses (OVs). OVs, including reovirus (RV), specifically infect and destroy cancer cells, while also activating the immune system to recognize and kill these cells. However, when used alone to treat MM in humans, RV has had only modest clinical success. One possible explanation that may underpin this is that MM can overexpress certain immunosuppressive immune-checkpoint proteins, like programmed-death ligand 1 (PD-L1), which allow it to functionally hide from the immune system. As such, strategies that combine OVs with blockade of the PD-L1 immunosuppressive axis are of interest.Our group has demonstrated that combining the standard-of-care drug, Bortezomib (BTZ), with RV, significantly enhances survival in a mouse model of MM. Interestingly, we found that the combination of RV+BTZ leads to a significant increase in tumor cell expression of PD-L1. As such, we believe that blocking the PD-L1 axis in addition to treatment with RV+BTZ will provide further survival benefit by promoting anti-tumor immune activity. This project will allow us to analyze the therapeutic potential of this combination for the treatment of MM, as well as assess its safety profile in mice. We are optimistic that positive results from this study could be leveraged into clinical trials in humans.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386583
Name
Meyers Daniel E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Overcoming Therapy Resistance in Multiple Myeloma with Oncolytic Virotherapy and Immune Checkpoint Inhibition
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immune Checkpoints; Immunotherapy; Multiple Myeloma; Murine Model; Oncolytic Viruses; Pd-1; Reovirus; Translational Therapeutics
Abstract
Multiple Myeloma (MM), a blood cancer of antibody-producing plasma cells, has a five-year survival rate of less than 50%. As such, novel therapeutic strategies for this disease are needed. One of the factors contributing to poor survival outcomes in MM is its innate ability to avoid immune destruction. Therefore, therapeutic strategies would ideally enhance the host's immune response against these malignant cells. One such strategy would be the utilization of oncolytic viruses (OVs). OVs, including reovirus (RV), specifically infect and destroy cancer cells, while also activating the immune system to recognize and kill these cells. However, when used alone to treat MM in humans, RV has had only modest clinical success. One possible explanation that may underpin this is that MM can overexpress certain immunosuppressive immune-checkpoint proteins, like programmed-death ligand 1 (PD-L1), which allow it to functionally hide from the immune system. As such, strategies that combine OVs with blockade of the PD-L1 immunosuppressive axis are of interest.Our group has demonstrated that combining the standard-of-care drug, Bortezomib (BTZ), with RV, significantly enhances survival in a mouse model of MM. Interestingly, we found that the combination of RV+BTZ leads to a significant increase in tumor cell expression of PD-L1. As such, we believe that blocking the PD-L1 axis in addition to treatment with RV+BTZ will provide further survival benefit by promoting anti-tumor immune activity. This project will allow us to analyze the therapeutic potential of this combination for the treatment of MM, as well as assess its safety profile in mice. We are optimistic that positive results from this study could be leveraged into clinical trials in humans.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Meyers, Daniel E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~